tetano
Editor, Senior Moderator
Biomed Pharmacother
. 2021 Mar 16;138:111518.
doi: 10.1016/j.biopha.2021.111518. Online ahead of print.
Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
Mona Sadat Mirtaleb[SUP] 1 [/SUP], Amir Hossein Mirtaleb[SUP] 2 [/SUP], Hassan Nosrati[SUP] 3 [/SUP], Jalal Heshmatnia[SUP] 4 [/SUP], Reza Falak[SUP] 5 [/SUP], Reza Zolfaghari Emameh[SUP] 6 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2020 and coronavirus disease 19 (COVID-19) was later announced as pandemic by the World Health Organization (WHO). Since then, several studies have been conducted on the prevention and treatment of COVID-19 by potential vaccines and drugs. Although, the governments and global population have been attracted by some vaccine production projects, the presence of SARS-CoV-2-specific antiviral drugs would be an urge necessity in parallel with the efficient preventive vaccines. Various nonspecific drugs produced previously against other bacterial, viral, and parasite infections were recently evaluated for treating patients with COVID-19. In addition to therapeutic properties of these anti-COVID-19 compounds, some adverse effects were observed in different human organs as well. Not only several attentions were paid to antiviral therapy and treatment of COVID-19, but also nanomedicine, immunotherapy, and cell therapy were conducted against this viral infection. In this review study, we planned to introduce the present and potential future treatment strategies against COVID-19 and define the advantages and disadvantages of each treatment strategy.
Keywords: Antiviral therapy, Immunotherapy; Antivirals; COVID-19; Cell therapy; Nanomedicine; SARS-CoV-2.
. 2021 Mar 16;138:111518.
doi: 10.1016/j.biopha.2021.111518. Online ahead of print.
Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
Mona Sadat Mirtaleb[SUP] 1 [/SUP], Amir Hossein Mirtaleb[SUP] 2 [/SUP], Hassan Nosrati[SUP] 3 [/SUP], Jalal Heshmatnia[SUP] 4 [/SUP], Reza Falak[SUP] 5 [/SUP], Reza Zolfaghari Emameh[SUP] 6 [/SUP]
Affiliations
- PMID: 33774315
- DOI: 10.1016/j.biopha.2021.111518
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2020 and coronavirus disease 19 (COVID-19) was later announced as pandemic by the World Health Organization (WHO). Since then, several studies have been conducted on the prevention and treatment of COVID-19 by potential vaccines and drugs. Although, the governments and global population have been attracted by some vaccine production projects, the presence of SARS-CoV-2-specific antiviral drugs would be an urge necessity in parallel with the efficient preventive vaccines. Various nonspecific drugs produced previously against other bacterial, viral, and parasite infections were recently evaluated for treating patients with COVID-19. In addition to therapeutic properties of these anti-COVID-19 compounds, some adverse effects were observed in different human organs as well. Not only several attentions were paid to antiviral therapy and treatment of COVID-19, but also nanomedicine, immunotherapy, and cell therapy were conducted against this viral infection. In this review study, we planned to introduce the present and potential future treatment strategies against COVID-19 and define the advantages and disadvantages of each treatment strategy.
Keywords: Antiviral therapy, Immunotherapy; Antivirals; COVID-19; Cell therapy; Nanomedicine; SARS-CoV-2.